Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CVM | 8-K | bullish | 6/10 | CEL-SCI (CVM) entered into a distribution and revenue-sharing agreement with Amarox for the registration, commercializat | May 14, 2026 |
| AURX | 8-K | bullish | 6/10 | Nuo Therapeutics reported Q1 2026 total revenue of $1.3M, up 169% YoY from $484K, driven by Aurix product sales growth o | May 14, 2026 |
| MAIA | 8-K | mixed | 5/10 | MAIA Biotechnology terminated its at-the-market (ATM) offering agreement with H.C. Wainwright & Co., effective seven bus | May 14, 2026 |
| RNA | 8-K | neutral | 4/10 | Atrium Therapeutics reported Q1 2026 collaboration revenue of $19.6M (vs $2.0M consensus), driven by a $15M milestone fr | May 14, 2026 |
| NCNA | 6-K | bullish | 6/10 | NuCana reported Q1 2026 results with a net loss of £3.9M, wider than the £2.5M loss in Q1 2025, driven by increased R&D | May 14, 2026 |
| FBRX | 8-K | mixed | 6/10 | Forte Biosciences reported Q1 2026 net loss of $1.24/share, wider than the $0.98 consensus miss, with no revenue. The ke | May 14, 2026 |
| EDSA | 8-K | neutral | 4/10 | Edesa Biotech reported fiscal Q2 2026 results with a net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/s | May 14, 2026 |
| MDCX | PRESS-RELEASE | bearish | 6/10 | Medicus Pharma reported Q1 2026 results with a net loss of $9.0M (vs. $5.1M a year ago), cash of $6.4M, and disclosed su | May 14, 2026 |
| HCWB | PRESS-RELEASE | bearish | 7/10 | HCW Biologics reported Q1 2026 GAAP net income of $3.5M ($0.37 EPS), a dramatic swing from a $2.2M loss a year ago, driv | May 14, 2026 |
| EDSA | PRESS-RELEASE | neutral | 4/10 | Edesa Biotech reported Q2 2026 net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/share) a year ago, as R | May 14, 2026 |
| HCWB | 8-K | bearish | 7/10 | HCW Biologics reported Q1 2026 net income of $3.5M vs a $2.2M loss in Q1 2025, driven by $6.5M in revenue from the Trimm | May 14, 2026 |
| TPST | 8-K | bearish | 7/10 | Tempest Therapeutics reported Q1 2026 results with a net loss of $27.7M ($2.53/share), significantly wider than the $10. | May 14, 2026 |
| LQDA | 144 | bearish | 5/10 | Director Roger Jeffs filed a Form 144 to sell 100,000 shares of Liquidia Corp common stock, with an estimated aggregate | May 14, 2026 |
| BGMSP | 8-K | bearish | 6/10 | Bio Green Med Solution (BGMSP) reported Q1 2026 results showing $0.8M in fire safety product revenue, a net loss of $0.2 | May 14, 2026 |
| TRAX | 8-K | neutral | 4/10 | First Tracks Biotherapeutics reported a net loss of $50.5M for Q1 2026, wider than the $47.2M loss in Q1 2025, as a clin | May 14, 2026 |
| GOVX | 8-K | bearish | 7/10 | GeoVax reported Q1 2026 net loss of $5.3M ($2.62/share) vs $5.4M ($11.20/share) in Q1 2025, with zero revenue after BARD | May 14, 2026 |
| FBIOP | 8-K | bullish | 6/10 | Fortress Biotech reported Q1 2026 net income attributable to common stockholders of $108.4M ($3.44 basic / $2.82 diluted | May 14, 2026 |
| RCKT | CLUSTER | neutral | 3/10 | Rocket Pharmaceuticals CEO Gaurav Shah sold $10K worth of shares and another insider sold $68K, totaling $78K in open-ma | May 14, 2026 |
| VNRX | 8-K | neutral | 4/10 | VolitionRx reported Q1 2026 revenue of ~$1.0M, up from $0.2M a year ago, but operating loss was only down 3% and net cas | May 14, 2026 |
| RNXT | 8-K | bullish | 5/10 | RenovoRx reported Q1 2026 revenue of $563,000, a 136% sequential increase from Q4 2025 and exceeding 50% of full-year 20 | May 14, 2026 |
| CRDF | 8-K | bullish | 7/10 | Cardiff Oncology reported Q1 2026 results with a net loss of $0.18 per share, slightly narrower than the $0.20 loss in Q | May 14, 2026 |
| MTEX | 8-K | bearish | 6/10 | Mannatech reported Q1 2026 net income of $1.0M ($0.49/diluted share), a significant improvement from a net loss of $1.5M | May 14, 2026 |
| MTVA | 8-K | neutral | 4/10 | MetaVia reported Q1 2026 net loss of $3.8M ($0.79/share) vs $3.7M ($3.93/share) in Q1 2025, with cash of $13.7M expected | May 14, 2026 |
| RKDA | 8-K | bearish | 6/10 | Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs | May 14, 2026 |
| ELUT | 8-K | neutral | 5/10 | Elutia reported Q1 2026 revenue of $3.1M (+6% YoY) and a GAAP net loss of $7.5M, widening from a $3.9M loss in Q1 2025, | May 14, 2026 |
| AEON | 8-K | neutral | 5/10 | AEON Biopharma reported Q1 2026 results with a net loss of $11.8M ($-0.29/share), compared to net income of $9.1M ($2.28 | May 14, 2026 |
| JSPRW | 8-K | bearish | 6/10 | Jasper Therapeutics reported Q1 2026 results with a net loss of $1.2M ($0.04/share) vs $21.2M loss ($1.41/share) in Q1 2 | May 14, 2026 |
| GRDX | 8-K | bearish | 7/10 | GridAI Technologies Corp. entered into two securities purchase agreements to raise a combined total of approximately $7. | May 14, 2026 |
| DARE | PRESS-RELEASE | neutral | 5/10 | Daré Bioscience reported Q1 2026 EPS of -$0.20, a 60% beat vs the -$0.50 consensus, but this is a mechanical artifact of | May 14, 2026 |
| ARTL | S-3/A | bearish | 6/10 | Artelo Biosciences filed Amendment No. 1 to its S-3 shelf registration statement solely to add a form of indenture (Exhi | May 14, 2026 |